Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

DexCom, Inc. - Common Stock (NQ:DXCM)

58.22 -9.98 (-14.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Exploring the top movers within the S&P500 index during today's session.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Discover which S&P500 stocks are making waves on Friday.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Why DexCom (DXCM) Stock Is Falling Today
Shares of medical device company DexCom (NASDAQ:DXCM) fell 14.8% in the afternoon session after the company reported underwhelming earnings. 
Via StockStory
Topics Artificial Intelligence Economy Government
Dexcom Stock Plunges 13% After-Hours As Q3 Margin Pressures Eclipse Record Profit — Retail Sees ‘Buy The Dip’ Setup
Via Stocktwits
Earnings Scheduled For October 30, 2025
 
Via Benzinga
An Overview of DexCom's Earnings
 
Via Benzinga
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive. 
Via Benzinga
Why DexCom Stock Is Crashing Today
The diabetes equipment provider had a strong quarter, but next year is looking weaker than expected. 
Via The Motley Fool
Topics Earnings
DXCM Investor Reminder:  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Gapping S&P500 stocks in Friday's session
Friday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session. 
Via Chartmill
Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); DexCom, Inc. (NASDAQ: DXCM); Humana Inc. (NYSE: HUM); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
Top S&P500 movers in Friday's pre-market session
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
DXCM Q3 Deep Dive: Margin Pressures Offset Strong Diabetes Access and Product Expansion
Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s... 
Via StockStory
Dexcom Stock, Down 13%, Haunted By Its 'Surprisingly Cautious' Outlook
Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled. 
Via Investor's Business Daily
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
These S&P500 stocks are moving in today's after hours session
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment. 
Via Chartmill
DexCom Inc (NASDAQ:DXCM) Reports Q3 2025 Earnings Beat Amid Stock Plunge on Guidance Concerns
DexCom Q3 2025 earnings beat estimates, but stock fell due to full-year revenue guidance that missed analyst expectations. 
Via Chartmill
Topics Earnings
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
DexCom (NASDAQ:DXCM) Beats Q3 Sales Expectations But Stock Drops
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be... 
Via StockStory
Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
From DexCom, Inc.
Via Business Wire
What Does the Market Think About DexCom Inc?
 
Via Benzinga
Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. and Certain Officers – DXCM
From Pomerantz LLP
Via GlobeNewswire
Should You Buy DexCom Stock Before Oct. 31?
The company hasn't had a great year. Is it about to turn things around? 
Via The Motley Fool
Topics Lawsuit
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
DEXCOM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DexCom, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DexCom (DXCM) Reports Earnings Tomorrow: What To Expect
Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know. 
Via StockStory
DCXM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. Investors
From Kirby McInerney LLP
Via Business Wire
Rosen Law Firm Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor
Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify. 
Via Benzinga
Topics Death Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.